New

New Innovations in Heart Failure

by

OSU Wexner Medical Center logo New Innovations in Heart Failure. Today We’ve invited two of Ohio State University’s cardiovascular experts to take us through the new therapies available to our heart failure patients and the practice changing guidelines to help us provide the best care to our patients. First, we have Heart Failure Cardiologist and Assistant Professor of Internal Medicine Dr Ajay Vallakati. Ajay specializes in Cardiac Amyloidosis. Second, we have Dr Indra Bole who is also an Assistant Professor of Internal Medicine and Heart Failure trained Cardiologist. His clinical interests are focused on cardiogenic shock, mechanical circulatory support, and heart transplant.

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to:

  • Discuss pharmacological management of heart failure
  • Recognize new heart failure therapies focusing on ivabradine, sacubitril-valsartan, and SGLT2i
  • Understand the benefit of SGTL2i in the population of patients with heart failure with reduced ejection fraction
  • Understand the benefit of SGTL2i in the population of patients with heart failure with preserved ejection fraction

You’ll also learn about the following:

  • Heart Failure Classification
  • Mortality
  • Goal Directed Medical Therapy
  • Advanced Therapies in Heart Failure

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About Lymphadenopathy and New Treatments for Lymphoproliferative Disorders

by

OSUWexnerbloglogo2014 Learn About Lymphadenopathy and New Treatments for Lymphoproliferative Disorders. Today on MedNet21, we are going to bring you up to date on the approach to lymphadenopathy and then tell you about some exciting new treatments for lymphoma that are changing the management of the disease. Our guests today are hematologist and Assistant Professor of Internal medicine, Dr. David Bond. And also Assistant Professor of Internal Medicine from the Division of Hematology, Dr. Yazeed Sawalha.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: review the mechanisms
of action and clinical data of (CAR) T cells and BiTEs in patients with relapsed/refractory B-cell non-Hodgkin lymphoma; highlight unique toxicities associated with CAR T cells and BiTEs: cytokines release syndrome and neurotoxicity; recognize the leading differential diagnosis considerations for a patient presenting with undifferentiated lymphadenopathy; and Differentiate diagnostic biopsy approaches including fine needle aspiration, core needle biopsy, and excisional lymph node biopsy.

You’ll also learn about the following:

  • New treatments for lymphoma
  • Cost and insurance coverage for CAR T-cells and bispecific T-cell engagers
  • What patients should expect during treatment
  • Stem cell transplant timing
  • Stem cell transplant versus bone marrow transplant

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.